Early trial tests promising new treatment for Tough-to-Treat ovarian cancer
NCT ID NCT06930755
Summary
This early-stage study is testing a new drug called NMS-03305293 combined with an existing chemotherapy (topotecan) for women with recurrent ovarian cancer. The main goals are to find the safest dose and see how well patients tolerate the combination. Researchers will also check if the treatment helps shrink tumors and how the body processes the new drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OSF Saint Francis Medical Center
RECRUITINGPeoria, Illinois, 61637, United States
-
Penn Medicine - Perelman Center for Advanced Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Washington University School of Medicine in St. Louis
RECRUITINGSt Louis, Missouri, 63130, United States
Conditions
Explore the condition pages connected to this study.